FGFR Inhibitor Achieves 42% Response Rate in Rare SDH-Deficient Stomach Tumors
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Summary
About 10–15% of gastrointestinal stromal tumors (GISTs) lack functional succinate dehydrogenase (SDH), making them resistant to standard KIT-targeted therapies. Researchers discovered that SDH loss causes widespread DNA hypermethylation that disrupts genomic insulators, spuriously activating growth-promoting FGF3 and FGF4 ligands and an FGFR1 signaling loop. A phase 2 trial tested rogaratinib, a pan-FGFR inhibitor, in 24 patients with advanced SDH-deficient GIST. Ten patients achieved partial responses, yielding a 41.7% objective response rate. Median progression-free survival reached 31 months, and 77% of patients were progression-free at one year. Side effects including high phosphate levels, fatigue, and diarrhea were manageable. The findings validate a novel treatment strategy targeting an epigenetically activated oncogenic pathway rather than a direct gene mutation.
Detailed Summary
Gastrointestinal stromal tumors driven by SDH deficiency represent a medically underserved population. Unlike the majority of GISTs harboring KIT or PDGFRA mutations that respond to imatinib, SDH-deficient GISTs lack an approved targeted therapy and tend to affect younger patients with limited options. Identifying a druggable mechanism in this subgroup has been a long-standing clinical need.
Researchers at Dana-Farber Cancer Institute and collaborating centers conducted a phase 2 trial (NCT04595747) testing rogaratinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, specifically in patients with advanced SDH-deficient GIST. The biological rationale was compelling: SDH complex loss leads to genome-wide DNA hypermethylation, which disrupts CTCF-bound insulators and aberrantly activates FGF3 and FGF4 ligands, which in turn drive tumor growth through an autocrine FGFR1 loop. This represents a targetable epigenetic oncogene activation mechanism rather than a somatic mutation.
Among 24 enrolled patients, 10 achieved confirmed partial responses, translating to a 41.7% objective response rate. The median progression-free survival was an impressive 31.0 months, with a 1-year PFS rate of 77.4%. These results substantially exceed historical benchmarks for this population. Toxicity was consistent with FGFR inhibitor class effects: hyperphosphatemia was common and served as a pharmacodynamic marker of on-target FGFR1 engagement, alongside manageable fatigue and diarrhea. Serial biopsies and whole-exome sequencing confirmed SDHx gene alterations and helped characterize resistance mechanisms.
The clinical implications are significant. This trial establishes rogaratinib as a potentially practice-changing option for SDH-deficient GIST and more broadly validates a therapeutic strategy rooted in epigenetic dysregulation rather than direct genetic mutation, a paradigm with relevance across multiple cancer types.
Caveats include the small sample size of 24 patients, the single-arm phase 2 design without a randomized comparator, and the summary being based on the abstract alone without access to full outcome tables or subgroup data.
Key Findings
- Rogaratinib achieved a 41.7% objective response rate in 24 patients with SDH-deficient GIST.
- Median progression-free survival was 31 months, with 77% of patients progression-free at 1 year.
- SDH loss causes DNA hypermethylation that aberrantly activates FGF3/FGF4 and an FGFR1 autocrine loop.
- Hyperphosphatemia confirmed on-target FGFR1 engagement; overall toxicity was manageable.
- Findings establish a proof-of-concept for targeting epigenetic oncogene activation in solid tumors.
Methodology
This was a single-arm, multicenter phase 2 trial enrolling 24 patients with advanced SDH-deficient GIST who received the pan-FGFR inhibitor rogaratinib. Primary endpoint was objective response rate; secondary endpoints included progression-free survival and safety. Exploratory analyses included serial biopsies with whole-exome sequencing and pharmacodynamic FGF ligand measurements.
Study Limitations
The trial enrolled only 24 patients, limiting statistical power and generalizability. The single-arm design without a randomized control arm makes it difficult to quantify treatment benefit against best supportive care or other regimens. This summary is based on the abstract only, as the full text was not accessible, so detailed subgroup analyses, durability of responses, and full safety data could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.